Subscribe



INVEST LIKE A PRO, WITH THE PROS!





RavenQuest BioMed (CSE:RQB) shares have jumped 24% in the past two sessions.

That's as investors wake up to the story that CEO *George Robinson* and his team have largely kept under wraps until now while they built out and proved out their **unique Orbital Garden** growing method.

Health Canada would tell you that RavenQuest BioMed is setting the standard for the industry.

<u>Here's our interview</u> with the company's highlyregarded CEO, George Robinson.

Sponsor content.

www.capitalideasmedia.com

Morning Need to Know

Getting you ready for your investing day

August 8, 2019

Written & compiled by Mark Bunting, Publisher, Capital Ideas Media



CANADIAN ANALYSTS' CALLS

INITIATIONS

Columbia Care (NEO:CCHW). Beacon Securities starts coverage with a "buy" rating and a price target of \$14 (Canadian), giving the stock a

projected 12 month return of 114%.

**

Medexus Pharmaceuticals (TSXV:MDP). Mackie Research maintains a "buy" rating and a price target of \$10.50, which implies **154% upside** potential.

Mackie calls the company a growth at a reasonable price play, that MDP is one of Canada's fastest growing specialty pharma companies, and that the share price is extremely undervalued. MDP is expected to release earnings numbers in two weeks.

Cormark Securities maintains a "buy" and a target of \$7.

Home Capital Group (TSX:HCG). RBC Dominion Securities upgrades to "outperform" and hikes the target to \$30 from \$25.

Franco-Nevada (TSX:FNV;NYSE:FNV).

Industrial Alliance Securities raises the target to \$136 from \$125 and maintains a "buy" rating after the company delivered its earnings results, saying that:

"Franco is the go-to option for generalists and/or those looking to hedge their portfolio with a quality, dividend paying, safe gold equity."

BSR REIT (TSX:HOM.UN). CIBC raises the target

to \$12.50 (U.S.) from \$11.75 and reiterates "outperformer".

Dream Industrial REIT (TSX:DIR.UN). Canaccord Genuity hikes the target to \$13.25 (Canadian) from \$12.25 and maintains"buy".

Finning Int'l (TSX:FTT). Raymond James upgrades to "outperform" and lifts the target to \$28 from \$27.

U.S. ANALYSTS' CALLS

Booking Holdings (NASDAQ:BKNG). Mizuho raises the target to \$2,150 (U.S.) from \$2,050.

STOCKS THAT MAY MOVE

goeasy (TSX:GSY) reported quarterly revenue and net income ahead of analysts estimates with Q2 revenue increasing 20% from last year to \$148 million (Canadian), and net income hitting \$19.6 million or \$1.26 per share compared to \$11.8 million or 82 cents a year ago.

Cronos Group (TSX:CRON;NASDAQ:CRON).

First Aphria and now Cronos has reported a surprise quarterly profit as revenue rose three-fold from last year although the company's adjusted core loss widened as expenses quadrupled. The shares were up nearly 7% in U.S. pre-market trading. **Pro REIT (TSX:PRV.UN)** has struck three deals to acquire seven properties in Ontario and Nova Scotia for nearly \$98 million. The REIT also said it will raise \$50 million in a bought-deal financing by issuing 7,150,000 units at \$7 each.

North American Construction Group (TSX:NOA;NYSE:NOA) has doubled its regular dividend to 16 cents per common share per year in the company's the first dividend increase since 2014.

Magna Int'l (TSX:MG;NYSE:MGA) has trimmed its sales forecast due to weaker demand and U.S. and China trade issues.

MARKETS

S&P/TSX and U.S. equity indices have started the session higher.

In economic data, China reported its strongest export growth since March.

CURRENCIES

The Canadian dollar is flat at \$0.7518 (U.S.)

COMMODITIES

West Texas Intermediate is up 2.6% at \$52.41 a barrel as Saudi Arabia hints at curtailing supply.

Gold is taking a breather after breaking through the \$1,500 an ounce level and sits at \$1,506.

DAILY UPDATE



The self-inflicted trade war between the U.S. and China is roiling stock markets and sending government bond yields to historically low levels.

But the new <u>Capital Ideas Digest</u> has four investment ideas not correlated to any trade war.

We've got research on an **alternative lender**, a **gold miner**, a company with a big catalyst in **U.S. sports gaming**, and a **cannabis oils extractor** breaking out technically.

Please email questions, comments or concerns to: customercare@capitalideasresearch.com

Access, ideas and insight.

Mark Bunting Publisher, Capital Ideas Media

www.capitalideasmedia.com





The information and recommendations made available here ("Information") by CIR and/or all affiliates is for informational purposes only and not to be used or construed as an offer to sell or a solicitation of an offer to buy any services or securities. You further agree that neither Capital Ideas Research will be liable for any losses or liabilities that may be occasioned as a result of the information or commentary provided in the letter. By accessing the site and reading this note, you accept and agree to be bound by and comply with the terms and conditions set out herein. If you do not accept and agree to the terms, you should not use this site or accept this email.

CIR is not registered as an adviser under the securities legislation of any jurisdiction of Canada and provides the Information pursuant to an exemption from the registration requirements that is available in respect of generic advice. The recommendations contained on the site and in this email are not tailored to the needs of particular persons and may not be appropriate for you depending on your financial position or investment goals or needs. You should apply your own judgment in making any use of the Information, especially as the basis for any investment decision. Prior to making any investment decision, we recommend that you seek outside advice from a qualified and registered investment advisor.

In no event will CIR be responsible or liable to you or any other party for any damages of any kind arising out of or relating to the use of, misuse of or inability to use this site and email. The Information is directed only at persons resident in Canada. Nothing in this site shall constitute an offer or solicitation to anyone in the United States of America or any jurisdiction where such offer or solicitation is not authorized or to any person to whom it is unlawful to make such a solicitation. If you choose to access this site or email from outside of Canada, you acknowledge that the Information is intended for use by persons resident in Canada only.

This is not an investment advisory, and should not be used to make investment decisions. Information in CIR is often opinionated and should be considered for information purposes only. No stock exchange anywhere has approved or disapproved of the information contained herein. There is no express or implied solicitation to buy or sell securities. The writers and editors of CIR may have positions in the stocks discussed above and may trade in the stocks mentioned. Don't consider buying or selling any stock without conducting your own due diligence.

Copyright © 2016 Capital Ideas Research, All rights reserved.

You are receiving this email because you are part of our investment network.

Add us to your address book

update subscription preferences

This email was sent to <u><<Email Address>></u> <u>why did I get this?</u> <u>unsubscribe from this list</u> <u>update subscription preferences</u> Capital Ideas Research · HSBC Bank Place · 10250 101 Street Suite 1803 · Edmonton, Alberta T5J 3P4 · Canada